Navigation Links
Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology

ommission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Accentia undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

Contact

Accentia Biopharmaceuticals, Inc., Tampa, FL
Susan Bonitz, PhD
813-864-2554 - Extension: 277
sbonitz@accentia.net
or
The Investor Relations Group, New York
Investors:
Adam Holdsworth
212-825-3210
aholdsworth@investorrelationsgroup.com
or
Media:
Janet Vasquez or Lynn Granito
212-825-3210
jvasqyez@investorrelationsgroup.com
lgranito@investorrelationsgroup.com


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
6. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
7. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
11. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
Post Your Comments:
Breaking Medicine Technology:Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer 2Within3 Expands into Mobile Applications 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 3Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 4Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 1Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 2Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 3Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 4Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 5Orexigen 28R 29 Therapeutics Releases New Efficacy Data for Contrave 28R 29 in Late Breaker Presentations at the 27th Annual Scientific Meeting of The 5754 6URI research couples method targets cancerous tumors 60165 1URI research couples method targets cancerous tumors 60165 2URI research couples method targets cancerous tumors 60165 3URI research couples method targets cancerous tumors 60165 4Scientists are first to observe the global motions of an enzyme copying DNA 10548 1Scientists are first to observe the global motions of an enzyme copying DNA 10548 2Scientists are first to observe the global motions of an enzyme copying DNA 10548 3Scientists are first to observe the global motions of an enzyme copying DNA 10548 4